Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation

Gene Therapy

Volumn 5, Issue 2, 1998, Pages 264-271

  Westermann, J ^a   Aicher, A ^a   Qin, Z ^b   Cayeux, S ^a,b   Daemen, K ^a   Blankenstein, Th ^b   Dorken B ^a   Pezzutto, B ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Dendritic cells; Retroviral interleukin 7 gene transfer

Indexed keywords

B7 ANTIGEN; BETA GALACTOSIDASE; CD1 ANTIGEN; CD14 ANTIGEN; CD86 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; VIRUS VECTOR;

ARTICLE; BLOOD; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTRON MICROSCOPY; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MICROSCOPY; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

UNIDENTIFIED RETROVIRUS;

EID: 0031885239     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300568     Document Type: Article

References (47)

1. Cox AL et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
2. Boon T et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994, 12: 337-365.
3. Doyle A et al. Markedly decreased expression of class I histocompatibility antigens, protein, and in RNA in human small-cell lung cancer. J Exp Med 1985; 161: 1135-1141.
4. Elliott BE, Carlow DA, Rodricks AM, Wade A. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 1989; 53: 181-245.
5. Restifo NP et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
6. Blankenstein T, Cayeux S, Qin Z. Genetic cancer vaccines. In: Blaustein MP et al (eds). Rev Physiol Biochem Pharmacol 129 Springer: Berlin, Heidelberg, New York, 1997, pp 3-49.
7. Pardoll DM. Cancer vaccines. Immunol Today 1993; 14: 310-316.
8. Austyn JM. The dendritic cell system and tumor immunity. In Vivo 1993; 7: 193-202.
9. Chen L et al. B7-1/CD80 transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum Cancer Res 1994; 54: 5420-5428
10. - T cells by B7-transfected melanoma cells. Science 1993; 259: 368-371.
11. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GMCSF and TNF-α cooperate in the generation of dendritic Langerhans cells Nature 1992; 360: 258-261.
12. Romani N et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93.
13. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med 1994; 179: 1109-1118.
14. Knight SC, Hunt R, Dore C, Medawar PB. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985; 82: 4495-4497.
15. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995; 16: 117-120.
16. Cohen PJ et al. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol 1994; 24: 315-319.
17. Flamand V et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605-610.
18. Celluzzi CM et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283-287.
19. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183: 317-322.
20. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nature Med 1995; 1: 1297-1302.
21. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 1996; 17: 131-137.
22. Alijagic S et al. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 1995; 25: 3100-3107.
23. Aicher A et al. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. Exp Hematol 1997; 25: 39-44.
24. Henderson RA et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC1). Cancer Res 1996; 56: 3763-3770.
25. Reeves ME et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996; 56: 5672-5677.
26. Watson JD et al Effect of IL-7 on the growth of fetal thymocytes in culture. J Immunol 1989; 143: 1215-1222.
27. Okazaki H et al. IL-7 promotes thymocyte proliferation and maintains immunocompetent thymocytes bearing a β or γ δ T-cell receptors in vitro: synergism with IL-2. J Immunol 1989; 143: 2917-2922.
28. Morrissey PJ et al. Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells. J Exp Med 1989; 169: 707-716.
29. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. Regulation of human T cell proliferation by IL-7. J Immunol 1990; 144: 938-941.
30. Grabstein KH et al. Regulation of T cell proliferation by IL-7. J Immunol 1990; 144: 3015-3020.
31. + T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291-1298.
32. Jicha DL, Mule JJ, Rosenberg SA. Interleukin 7 generates anti-tumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991; 174: 1511-1515.
33. Cayeux S et al. Tumor cells cotransfected with interleukin-7 and B7-1 genes induce CD25 and CD28 on tumor infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995; 25: 2325-2331.
34. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
35. + blood progenitors for anticancer therapy Exp Hematol 1995; 23: 1463-1471.
36. Steinman RM. The dendritic cell system and its role in immunogenioty. Annu Rev Immunol 1991; 9: 271-296.
37. Zitvogel L et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
38. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577-587.
39. Lynch DH, Miller RE. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med 1994; 179: 31-42.
40. Li KJ et al. Retrovirus-mediated gene transfer into human bone marrow stromal cells: studies of efficiency and in vivo survival in SCID mice. Eur J Hematol 1995; 55: 302-306.
41. Patel PM et al Generation of Interleukin-2-secreting melanoma cell populations from resected metastatic tumors. Hum Gene Ther 1994; 5: 577-584
42. Kang SM et al. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 1992; 257: 1134-1138.
43. Boussiotis VA et al. Prevention of T cell anergy by signaling through the γ c chain of the IL-2 receptor. Science 1994; 266: 1039-1042.
44. Filion MC et al. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur J Immunol 1995; 25: 3123-3127.
45. Hsu FJ et al. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 52-58.
46. Miller DA, Rosman DJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989; 7: 980-987
47. - cells even in the presence of exogenous IL-2. Blood 1989; 74: 2270-2277.